Plus Therapeutics Files 8-K: Officer Changes and Compensation Details
Ticker: PSTV · Form: 8-K · Filed: 2026-04-09T08:01:12-04:00
Sentiment: neutral
Topics: officer-change, compensation, corporate-governance
TL;DR
PLUS THERAPEUTICS made officer changes and filed compensation details. Watch for new leadership impact.
AI Summary
On April 8, 2026, PLUS THERAPEUTICS, INC. filed an 8-K report detailing the departure of a director and the appointment of a new officer. The filing also includes information on compensatory arrangements for certain officers, though specific dollar amounts and names of individuals involved in these arrangements are not detailed in the provided text.
Why It Matters
Changes in corporate officers and details about their compensation can signal shifts in company strategy or financial priorities, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Officer departures and appointments, along with compensation disclosures, can indicate internal shifts that may affect the company's future direction and stability.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Filer of the 8-K report
- 0001095981 (company) — CIK number for PLUS THERAPEUTICS, INC.
- 2026-04-08 (date) — Period of Report for the 8-K filing
- 2026-04-09 (date) — Filing Date and Acceptance Date of the 8-K report
FAQ
Who departed from PLUS THERAPEUTICS, INC. as a director?
The filing indicates the departure of a director, but the specific name is not provided in the summary text.
Who was appointed as a new officer at PLUS THERAPEUTICS, INC.?
The filing mentions the appointment of a certain officer, but the specific name and title are not detailed in the provided text.
What specific compensatory arrangements are detailed for officers?
The filing notes that compensatory arrangements of certain officers are included, but the specific details and dollar amounts are not elaborated in the provided text.
What is the CIK number for PLUS THERAPEUTICS, INC.?
The CIK number for PLUS THERAPEUTICS, INC. is 0001095981.
What is the filing date of this 8-K report?
The 8-K report was filed and accepted on April 9, 2026.
From the Filing
EDGAR Filing Documents for 0001193125-26-148920 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-148920 Filing Date 2026-04-09 Accepted 2026-04-09 08:01:12 Documents 10 Period of Report 2026-04-08 Items Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K pstv-20260408.htm iXBRL 8-K 54852 2 EX-10.1 pstv-ex10_1.htm EX-10.1 123936 Complete submission text file 0001193125-26-148920.txt 296301 Data Files Seq Description Document Type Size 3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pstv-20260408.xsd EX-101.SCH 31920 13 EXTRACTED XBRL INSTANCE DOCUMENT pstv-20260408_htm.xml XML 4716 Mailing Address 4200 MARATHON BLVD. SUITE 200 AUSTIN TX 78756 Business Address 4200 MARATHON BLVD. SUITE 200 AUSTIN TX 78756 737.255.7194 PLUS THERAPEUTICS, INC. (Filer) CIK : 0001095981 (see all company filings) EIN. : 330827593 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-34375 | Film No.: 26849860 SIC : 3841 Surgical & Medical Instruments & Apparatus (CF Office: 08 Industrial Applications and Services)